Antiplatelet therapy - A pharmacologist´s perspective

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F13%3A43907278" target="_blank" >RIV/00216208:11120/13:43907278 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.crvasa.2013.03.003" target="_blank" >http://dx.doi.org/10.1016/j.crvasa.2013.03.003</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2013.03.003" target="_blank" >10.1016/j.crvasa.2013.03.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Antiplatelet therapy - A pharmacologist´s perspective

Popis výsledku v původním jazyce

There are only few areas of cardiology that have witnessed such dramatic innovations as that occurring in the treatment and prophylaxis of thrombotic events. Antithrombotic (i.e., antiplatelet and anticoagulation) therapy plays a pivotal role in the prophylaxis of the pandemic of cardiovascular disease. Given the host of triggers activating primary hemostasis, various therapeutic strategies are currently available. The current approach, monotherapy or dual therapy or, possibly, combination therapy withantiplatelet and anticoagulant agents is selected based on the risk of a thrombotic event, dominant disease, and the risk of bleeding. The main problem associated with the current therapeutic strategy was not an insufficient effect, but major inter-individual variability of effect resulting in therapy failure or an unacceptable risk of bleeding documented in a non-negligible proportion of patients. Hence there is a drive for devising new antiplatelet strategies and innovation in (already

Název v anglickém jazyce

Antiplatelet therapy - A pharmacologist´s perspective

Popis výsledku anglicky

There are only few areas of cardiology that have witnessed such dramatic innovations as that occurring in the treatment and prophylaxis of thrombotic events. Antithrombotic (i.e., antiplatelet and anticoagulation) therapy plays a pivotal role in the prophylaxis of the pandemic of cardiovascular disease. Given the host of triggers activating primary hemostasis, various therapeutic strategies are currently available. The current approach, monotherapy or dual therapy or, possibly, combination therapy withantiplatelet and anticoagulant agents is selected based on the risk of a thrombotic event, dominant disease, and the risk of bleeding. The main problem associated with the current therapeutic strategy was not an insufficient effect, but major inter-individual variability of effect resulting in therapy failure or an unacceptable risk of bleeding documented in a non-negligible proportion of patients. Hence there is a drive for devising new antiplatelet strategies and innovation in (already

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor et Vasa

ISSN

0010-8650

e-ISSN

—

Svazek periodika

55

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

9

Strana od-do

"e86"-"e94"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—